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Therapeutic Discovery
Inhibition of ATR-Dependent Signaling by Protoapigenone
and Its Derivative Sensitizes Cancer Cells to Interstrand
Cross-link–Generating Agents In Vitro and In Vivo
Hui-Chun Wang1,2, Alan Yueh-Luen Lee3, Wen-Cheng Chou1,4, Chin-Chung Wu1,2,
Chao-Neng Tseng1,2, Kevin Yen-Ting Liu1, Wen-Lien Lin1, Fang-Rong Chang1,2,
Da-Wei Chuang1, Attila Hunyadi1,6, and Yang-Chang Wu1,5
Abstract
DNAdamage caused during cancer treatment can rapidly activate the ataxia telangiectasia-mutated (ATM)
andATMandRad3-related (ATR)-dependentphosphorylation ofChk2andChk1kinases,which arehallmarks
of theDNAdamage response (DDR). Pharmacologic inhibition ofATR causes a synthetic lethal effect onATM-
orp53-defective cancers, suggesting that such inhibition is an effectiveway to improve the sensitivity of cancers
to DNA-damaging agents. Here, both the natural compound protoapigenone (WYC02) and its synthetic
derivative WYC0209 exhibited cytotoxic effects on various cancer cell lines. WYC02 causes chromosomal
aberration in the mitotic spreads of Chinese hamster ovary cells. Interestingly, cancer cells did not exhibit
typical DDR markers upon exposure to WYC02 and WYC0209 (WYCs). Further investigation into the
molecularmechanismsofWYCs function revealed that theyhave apotential ability to inhibitDDR,particularly
on activation of Chk1 and Fanconi anemia group D2 protein (FANCD2), but not Chk2. In this way, WYCs
inhibited ATR-mediated DNA damage checkpoint and repair. Furthermore, when combined with the DNA
cross-linking agent cisplatin, treatmentwithWYCs resulted in increased tumor sensitivity to interstrand cross-
link–generating agents both in vitro and in vivo. Our results therefore especially implicate WYCs in enhancing
tumor chemosensitivity when the ATR checkpoint is constitutively active in states of oncogene-driven
replicative stress or tolerance to DNA-interfering agents. Mol Cancer Ther; 11(7); 1443–53. 2012 AACR.
Introduction
Ataxia telangiectasia-mutated (ATM) and ATM and
Rad3-related (ATR) are 2 members of the phosphoinosi-
tide 3-kinase–related protein kinase family that play a
central role in DNA damage response (DDR) coordina-
tion; they also function in the signaling machinery of cell-
cycle arrest, DNA repair and transcription, and cell death.
Although ATM is predominantly activated in response to
DNA strand breaks, ATR is activated in response to
damage arising from UV rays or replication block; both
kinases activate signaling cascades that involve 2 check-
point kinase effectors, Chk1 and Chk2, whose roles were
previously suggested to be redundant (1). In contrast to
ATM, ATR has been reported to be indispensible for cell
growth and for life. ATR knockout mouse embryos died
early due to mitotic catastrophe characterized by incom-
plete DNA replication and chromosomal fragmentation
(2, 3). Moreover, ATR gene mutations are rarely found
in humans. The only mutation variants that can survive
are heterozygous or hypomorphic variants. Further-
more, cells derived from patients with Seckel syndrome
exhibit cellular features associated with ATR signaling
defects. Consistent with this phenotype, Seckel-like
mouse embryonic cells showed accelerated aging due
to replicative stress, exhibiting an accumulation of
lethal chromosomal breaks (4, 5). However, with regard
to its role in regulating the replication checkpoint, ATR
is activated by most cancer chemotherapeutic agents
that target DNA in replicating cells. Therefore, inhibi-
tion of ATR signaling is a valid and promising strategy
that can improve efficiency of chemotherapy or
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radiotherapy (6, 7). Thus far, several inhibitors of DDR-
related kinases, including Chk1 and Chk2, have been
successfully used alone or in combination with each
other in clinical trials (8, 9). Recently, several chemicals
that inhibit ATR kinase activity in vitro were used to
support the hypothesis that ATR kinase can be targeted
to improve cancer therapy (10–14). Because most of
these studies are in their initial stages, it is imperative
to focus more efforts toward investigating strategies to
inhibit ATR signaling.
WYC02 (Fig. 1A) is a flavonoid that we previously
isolated and identified from the whole plant extract of
Thelypteris torresiana, a fern species native to Taiwan. This
compound was originally screened for cytotoxicity func-
tion; using a colorimetric cytotoxicity assay, WYC02
showed therapeutic effects and was a lead compound for
potential anticancer drug development (15–17). In previ-
ous studies, WYC02 and its more potent analogWYC0209
(Fig. 1A) were shown to induce oxidative stress, conse-
quently activating the p38 and c-jun-NH2-kinase (JNK)
1/2 mitogen-activated protein kinase (MAPK) path-
ways following cell-cycle arrest and apoptosis in several
cancer cell types. These compounds were also found to
reduce the size of tumor xenografts in nude mice with-
out exerting toxic effects on the recipient (18–22).
Recently, WYCs were found to induce chromosomal
breakage through oxidative stress (18, 20), implicating
a role for WYCs in interfering with DNA metabolism.
To date, the biomolecular actions and implications of
this WYC-mediated interference are mostly undeter-
mined. Here, we found that WYCs are capable of inhi-
biting DNA damage–induced activation of ATR targets
Chk1 and Fanconi anemia group D2 protein (FANCD2),
which then sensitize tumor cells to chemotherapy, and
finally result in tumor size reduction in mice. Our
results propose that these new flavonoid compounds
are of noteworthy potential to treat cancers by inducing
replication stress via the inhibition of ATR signaling.
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Figure 1. WYC02 induces chromosomal aberration with no marked DDR. A, illustration of the chemical structure of selective ATM inhibitor KU55933,
WYC02, and its derivative WYC0209. B, mitotic spreads were prepared from WYC02-treated CHO cells at the indicated concentrations. The
representative architecture of normal and aberrant chromosomes is shown. The numbers for different types of aberrations were counted from 200
mitotic cells in 2 independent slides is shown in Table 1. C, immunoblots showing DDR by detecting phosphorylation of ATM Ser1981 (ATM-S1981p),
Chk1 Ser345 (Chk1-S345p), Chk2 Thr68 (Chk2-T68p), P53 Ser15 (P53-S15p), P38MAPK Thr180/Tyr182 (P38-T180p/Y182p), or MAPKAPK2 Thr334 (MK2-
T334p) following exposure of HEK293T cells to 10 mmol/L WYC02 for the indicated times. Cells treated with 0.1 mmol/L H2O2 for 30 minutes served as
the positive control.
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Materials and Methods
Cell culture and treatment
MDA-MB-231 [breast adenocarcinoma; ATCCHTB-26,
BCRC 60425] and A549 (lung adenocarcinoma; ATCC
CCL-185, BCRC 60074) human cell lines were purchased
from Bioresource Collection and Research Center (BCRC)
and were authenticated by American Type Culture Col-
lection (ATCC). U2OS (osteosarcoma), HeLa (cervical
adenocarcinoma), and HEK 293T (embryonic kidney
cells) human cell lines were provided by Dr. Sheau-Yann
Shieh (Institute of Molecular Biology, Academia Sinica,
Taipei, Taiwan). Cells were maintained in Dulbecco’s
Modified Eagle’s Medium (Sigma-Aldrich) supplemen-
ted with 10% FBS (Gibco). For DDR induction, freshly
diluted H2O2 (Merck) was added to the culture medium
1 hour before the cells were harvested. For UV irradiation
treatment, the cells were irradiated for 10 J/m2 by a cross-
linker (UVP CL-1000) 1 hour before analysis. WYC02 and
WYC0209 were isolated and synthesized as described
previously (15–17).
In vitro chemosensitization assay
To evaluate in vitro chemosensitization, cells were seed-
ed in 6-well plates 1 day before the experiment at a density
of 100 to 400 cells perwell. The drugswere incubatedwith
the cells for 6 hours, afterwhich themediumwas replaced
with fresh drug-free FBS-containing medium. The colo-
nies became visible and were counted 7 to 10 days later
with 0.1% crystal violet staining following image capture
by a CCD camera (LAS 4000 mini; Fujifilm).
Flow cytometry
To evaluate the effect of DNA damage checkpoint
activation on cell-cycle distribution, the cells were har-
vested at indicated time points and fixed with methanol
for at least 2 hours. The DNA was then stained with a
solution containing propidium iodide (PI) and RNase A
(Sigma-Aldrich). Fluorescently labeled cells were subse-
quently analyzed by the flow cytometer (LSR II; BD
Biosciences) with a suitable selection of excitation and
emission wavelengths. The percentages of different fluo-
rescent cell populations were analyzed by WinMDI ver-
sion 2.9 (The Scripps Research Institute).
In vitro chromosome aberration test
In brief, 5  105 Chinese hamster ovary (CHO) cells
were seeded in 60-mmdishes 1daybefore the experiment.
WYC02-induced structural chromosomal changes after 20
hours were compared with that of the cells cultured in 2
mmol/L mitomycin C (MMC). At 18 hours after WYC02,
0.1 mg/mL colchicine was added for 2 hours, and meta-
phase cells were collected by shaking them off the dishes.
Mitotic cells were treated with 0.5% KCl for 10 minutes
and fixed with a 3:1 mixture of methanol:glacial acetic
acid. The cellswere then spread on slides for chromosome
staining with 5% Giemsa solution. We then analyzed the
chromosome structure of 200well-spreadmetaphase cells
(100 metaphase cells per experiment) under a 100 oil
immersion objective.
Plasmids and siRNAs
The plasmids ATR, ATRIP, and claspin were kindly
provided byDr. X.Wu (The Scripps Research Institute, La
Jolla, CA), and TopBP1 was provided by Dr. J. Chen
(University of TexasMDAnderson Cancer Center, Hous-
ton, Texas). The siRNA sequences of the target ATM (50-
AAGCGCCTGATTCGAGATCCT-30), ATR (50-CCTCCG-
TGATGTTGCTTGATT-30), DNA-PKcs (50-GATCGCAC-
CTTACTCTGTTGA-30), and the random sequence that
served as the control (50-AAGTCAATATGCGACT-
GATGG-30) were synthesized by Sigma-Proligo (23, 24).
All transfections inHEK293T cells were carried out by the
calcium phosphate precipitation method.
Western immunoblotting
Cell lysatepreparations, gel electrophoresis, and immu-
noblotting were carried out as previously described (23).
The binding of primary antibodies were detected by
horseradish peroxidase–coupled secondary antibodies
Table 1. WYC02 induces chromosomal aberration in CHO cells
Type of structural aberrations (numbers)
Treatment
Concentration
(mmol/L) TB TD TR QR R CR DC PP PC
Average aberrant
metaphases (%)a
DMSO control 0.00 0 0 0 0 0 0 0 1 0 0.5
WYC02 2.17 2 0 4 3 1 0 0 3 0 6.5
WYC02 4.35 1 1 13 9 2 0 0 1 1 14
Mitomycin C 2.00 2 3 42 29 0 2 1 0 5 42
NOTE: Two hundred cells per treatment were analyzed for chromosomal aberration. The total numbers of chromatid break (TB),
chromatid deletion (TD), triradial (TR), quadriradial (QR), ring (R), complex rearrangement (CR), dicentric (DC), polyploid (PP), and
pulverizedcell (PC)were indicated.Others, chromosomegap, chromosomebreak, chromosomedeletion, andchromatidgap,werenot
observed in this experiment.
aIndicated statistic signiﬁcantly for tested versus control group by t test, respectively.
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(Jackson ImmunoResearch) followed by enhanced chemi-
luminescence (Millipore). The images of nonsaturated
bands were captured by a luminescent image analyzer
(LAS-4000 mini; Fujifilm). The antibodies used in this
study are listed in Supplementary Materials.
DNA homologous recombination repair assay
DNA constructs of the recombination substrate
pHPRT-DRGFP, in which the I-SceI site lies within 1
copy of 2 mutated tandem repeated GFP genes, and
the I-SceI endonuclease expression vector pCBASceI,
were originally constructed by Dr. M. Jasin (25). In brief,
we generated a stable pHPRT-DRGFP construct in HeLa
cells and evaluated the chromosomal breaks generated
by I-SceI endonuclease expression. Six hours after
pCBASceI was delivered into the cells, completemedium
with or without WYC02 or WYC0209 was replaced onto
the cells. Forty-eight hours after delivery, the efficiency
of chromosomal homologous recombination repair
(HRR) was obtained as the percentage of GFP-positive
cells, which was assessed by flow cytometry.
Human xenograft tumors in nude mice
Human breast cancer MAD-MB-231 cells were har-
vested from the culture, resuspended in mediumwithout
serum at 1  108 cells/mL, and 0.1 mL of this suspension
was subcutaneously injected into the right flank of female
nude mice (BALB/cAnN-Foxn1nu/Crl Narl; purchased
from the National Science Council Animal Center).
Tumor-injected mice that successfully developed tumors
that grew to approximately 50 to 100 mm3 in volume
were randomly sorted into groups and used for the
experiments. Control vehicle or 2 mg/kg of cisplatin with
or without 0.2 mg/kg of WYC0209 was administered
intraperitoneally every 4days throughout the experiment.
The drug formulations are described in Supplementary
Materials.
Results
WYC02 induces chromosomal aberrations but does
not produce marked DDR
Previously,WYC02 andWYC0209were shown to cause
DNA strand breaks and apoptosis in lung and prostate
cancers (18, 20), suggesting that inducing DNA damage
may be the potential mechanism underlying the antican-
cer effect ofWYCs. To test this hypothesis,we investigated
the cytogenetic effect of WYC02 on CHO cells (Fig. 1B).
Low WYC02 concentrations produced dose-dependent
increases in chromosomal structural changes, such as
breakages, radials, and chromosomal polyploidy, similar
to the effects seen with MMC treatment; however, the
completemitotic chromosome couldnot beobtainedupon
high-dose WYC02 treatment. Because MMC can induce
DDR in many cancers, we investigated what kind of DDR
signaling was activated by WYC02. Surprisingly, high
doses of WYC02 in HEK293T cells did not induce notice-
able changes in the putative DDR signaling, which we
measured by analyzing the phosphorylation of the ATM-
dependent Chk2 Thr68 residue and the ATR-dependent
Chk1 Ser345 residue (Fig. 1C).We did observe thatWYC02
treatment caused slight accumulation of the p53 protein,
which could have been the result of several posttransla-
tional modifications. However, phosphorylation of the
p53 Ser15 residue did not contribute to this WYC02-
induced p53 protein accumulation, suggesting that
WYC02 does not directly damage DNA because DNA
damage normally stimulates ATM/ATR-dependent p53
Ser15 phosphorylation. Our result is similar to previous
reports that p38MAPK is activated byWYC02 (19, 21, 22),
as its downstream target MAPKAPK2 was found to be
phosphorylated starting as early as 2 hours after WYC02
exposure (Fig. 1C).We repeated theWYCs experiment on
lung and breast carcinoma cell lines A549 and MDA-MB-
231 cells, respectively, and obtained similar results. Con-
sistently, no marked changes in Chk1 and Chk2 phos-
phorylation signalingwere detected even at high doses of
either drug for as long as 8 hours after drug treatment
(Supplementary Fig. S1A). The cytotoxic effect by WYCs
on cancer cells was determined byMTT assay at 48 hours
of incubation (Supplementary Fig. S1B); our data indicat-
ed that the IC50 value range for cytotoxicity was similar to
those inprevious reports, confirming thatWYCsare stable
compounds that do not directly cause DNA damage.
WYC02 andWYC0209 inhibit Chk1 phosphorylation
after DNA damage
Understanding the mechanism by which the WYCs
compounds cause chromosomal breakages and other
abnormalities might aid in identifying their targets. We
hypothesized that genes with functions associated with
DNA damage checkpoints and/or DNA repair might be
targeted byWYCs. To test this hypothesis,we assessed the
effects of WYCs on DDR induced by H2O2. WYC02 was
found to inhibit Chk1, but promoteChk2phosphorylation
in A594 cells treated with 0.1 mmol/L H2O2 for 2 hours;
however, ATM autophosphorylation was not affected
(Fig. 2A). Pretreatment of cells with okadaic acid (OA; a
phosphatase inhibitor) orMG132 (a proteasome inhibitor)
could not reverse the WYC02-induced inhibition of Chk1
phosphorylation, indicating that the inhibition does not
occur due to phosphatase activation or proteasome deg-
radation by other regulatory factors (Fig. 2B). Further-
more, we investigated other sources of DNA stimuli
specific for ATR activation; our results show that UV-
induced Chk1 phosphorylation was dose dependently
inhibited by WYCs within different cells (Fig. 2C). In
response to DNA double-strand breaks (DSB), FANCD2
is known to be monoubiquitinated on K561 (FANCD2-
Ub) in an ATR-dependent manner to stimulate repair (26,
27). We showed that FANCD2-Ub was also inhibited by
WYCs (Fig. 2A and C); furthermore, ATR inhibition by
WYCs was also observed in cells treated with currently
prescribed chemotherapeutic agents (Supplementary Fig.
S2). Collectively, these findings indicate that WYCs can
modify ATR signaling after various types of DNA
Wang et al.
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damage. Interestingly, WYC0209 was more potent than
WYC02 in inhibiting Chk1 phosphorylation and cytotox-
icity (Fig. 2C and Supplementary Fig. S1B). We speculate
that the replacement of 2 hydroxyl groups onWYC02with
an additional benzene ring contributes positively to this
ATR inhibition; however, the definite pharmacophores
need to be further investigated when the ATR protein
structure is resolved.
Target specificity of WYC02 andWYC0209 for ATR-
mediated signaling inhibition
To elucidate the specificity of the WYC inhibition on
ATR-mediated signaling, we compared the change
between cells treated with WYCs or the ATM-specific
inhibitor KU55933 (Fig. 1A) before the induction of DDR.
After H2O2 damage, ATM is thought to be the principal
responder, and KU55933 treatment strongly inhibited
ATM-mediated Chk2 phosphorylation specifically, but
its effect on ATR-mediated Chk1 phosphorylation was
small (Fig. 3A, top). In contrast, after hydroxyurea (HU; a
replication blocker) damage, ATR is thought to be the
principal responder, and WYCs treatment significantly
inhibited Chk1 phosphorylation, but only slightly inhib-
ited Chk2 phosphorylation (Fig. 3A, bottom). Using these
pharmacologicmethods,we showed that the specificity of
DDR inhibition between WYCs and KU55933 was
completely different. To strengthen the argument that
WYCs specifically inhibit ATR signaling, small inhibitory
RNAs against ATM, ATR, and the catalytic subunit of
DNA protein kinase (DNA-PKcs) were introduced into
HEK293T cells before exposure toUVorH2O2.Our results
showed that WYCs completely inhibited UV- or H2O2-
induced Chk1 phosphorylation in a manner similar to
siRNA knockdown of ATR, but not ATM or DNA-PKcs
(Fig. 3B and Supplementary Fig. S3). The siRNAs against
ATMandDNA-PKcs decreased theUV- orH2O2-induced
Chk2 phosphorylation, which were not altered by the
addition of WYC02, but were increased by WYC0209
treatment. Interestingly, neither siRNA targeted to ATM
or ATR nor DNA-PKcs affected the WYC0209-mediated
increase in Chk2 phosphorylation. Because a high dose of
WYC0209 itself slightly induces Chk2 activation (Supple-
mentary Fig. S1), the increasedChk2phosphorylationwas
likely a synergistic effect due to DNA damage. To further
identify the specific mediator that contributes to the effect
of WYC02 on the initiation of ATR kinase activation, we
tested whether TopBP1, ATRIP, and claspin were
involved, as they have been identified as mediators of
ATR kinase activation (28). Our results showed that over-
expression of ATRIP or TopBP1 did not reverse the inhib-
itory effect of WYC02 on Chk1 phosphorylation, whereas
overexpression of claspin orATRdid (Fig. 3C), suggesting
that WYC02 might affect the function of ATR or claspin
contributing to ATR signaling inhibition.
WYC02 and WYC0209 impair the functions of DNA
damage checkpoints and DNA repair
Previously, it has been shown that S–M and G2–M
checkpoints are activated by ATR in response to different
types of DNA damage (6, 7). Of these, the G2–M check-
point involves ATM and ATR in collaboration, whereas
the S–M checkpoint is mediated solely by ATR. To
maintain genetic integrity, ATR can prevent premature
mitotic entry in the event of incomplete DNA replication
or unrepaired DNA damage (6). To evaluate the effect
of WYCs on these ATR-associated DNA damage
Figure 2. WYCs inhibit DNA
damage-induced Chk1
phosphorylation. A, immunoblots
showing DDR by detecting
phosphorylation of ATM, Chk1,
Chk2, and monoubiquitination of
FANCD2 following exposure of A549
cells to 0.1 mmol/L H2O2 for 2 hours
with or without pretreatment of the
indicated doses of WYC02. B, A549
cells pretreated with 8 mmol/L
WYC02combinedwith 50mmol/LOA
or 20 mmol/L MG132 for 30 minutes
and subjected to 10 J/m2 UV for
1 hour to induce DDR. C, dose-
dependent effect of WYC02 (left) and
WYC0209 (right) on the inhibition of
UV-inducedChk1phosphorylation in
A549 (top) and MDA-MB-231
(bottom) cells. Cells were pretreated
with chemicals for 30 minutes and
subjected to 10 J/m2 UV for 1 hour
to induce DDR.
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checkpoints, we observed the effect of WYCs on mitotic
entry following HU or cisplatin treatment. In MDA-MB-
231 cells, HU and cisplatin significantly decreased the
number ofmitotic cells, indicating that the S–MandG2–M
checkpoints are intact in MDA-MB-231 cells (Fig. 4A).
WYCs or KU55933 treatment increased the percentage of
mitotic cells in cisplatin-treated cells, suggesting that all of
these compounds inhibited the damage-induced G2–M
checkpoint. However, WYCs, but not KU55933, signifi-
cantly increased the HU-induced mitotic entry that is
specific for the S–M checkpoint, indicating that WYCs
specifically impaired this distinctive checkpointmediated
solely by ATR (Fig. 4A).
ATR function is also linked to DNA repair via its
coupled targets (29). To examine the effect of WYCs
treatment on DNA repair, we carried out an HRR assay
inHeLacells.Our result showed that chromosomalbreaks
normally repaired by HRR were dose dependently inhib-
itedbyWYC02at lowconcentrations.WYC0209produced
similar effects at doses thatwere 10-fold lower than that of
WYC02 (Fig. 4B). From these results, we assumed that the
cells carrying unrepaired DNA would enter into mitosis
following DNA damage. To verify this assumption, we
analyzed the DNA-damage marker gH2AX on mitotic
cells using immunofluorescence staining. As expected,
the numbers of large gH2AX foci were increased upon
addition of WYCs in both unperturbed and perturbed
mitotic cells (Fig. 4C and Supplementary Fig. S8), suggest-
ing thatWYCs increase DNAdamage inmitotic cells. The
chromosomes became flat and aggregated after WYC
treatment, differing from the 3-dimensional and hair-like
appearance of normal chromosomes at metaphase.
WYC02 and WYC0209 enhance chemosensitivity
Inhibition of the checkpoint and repair mechanisms
leads to chemosensitization in cancers. We questioned
whether WYCs could function as sensitizers for the che-
motherapeutic drug cisplatin that has been shown to
induce ATR activation as well as FANCD2 monoubiqui-
tination, which is the vital step for DNA crosslink repair
(26, 30, 31). We found that WYCs treatment decreased the
cisplatin-induced Chk1 phosphorylation and FANCD2
monoubiquitination in A549, MDA-MB-231, and U2OS
cells (Fig. 5A). Using the same doses, WYC0209 not only
inhibits monoubiquitination of FANCD2 but also affects
FANCD2 protein stability; these data emphasize that
WYC0209 has more potent inhibitory effects as than
WYC02.We further treated individual cells with cisplatin
in combination with several varying doses of WYCs and
counted survival colonies to determine their ability to
survive after cisplatin-induced damage. Our results
showed that WYCs effectively decreased the clonogenic
survival in cisplatin-treatedMDA-MB-231 and A549 cells
in the nanomolar dose range (Fig. 5B). To investigate the
chemosensitization effect of low-dose WYCs in vivo, we
established a tumor xenograft in nude mice with human
MDA-MB-231 tumor cells, which are considered to be
more resistant to cisplatin and are also sensitive to
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treatment with WYCs, at least as compared with A549
cells (Supplementary Fig. S1B and S4). When the mice
were treated with 0.2 mg/kg WYC0209 in combination
with 2 mg/kg cisplatin, the tumor inhibitory effect was
greater than that of cisplatin treatment alone (Fig. 5C).
However,WYC02 unexpectedly did not affect the cisplat-
in sensitivity ofMDA-MB-231 tumorswhen a higher dose
of 2mg/kgwasused in our experiments (data not shown).
The pharmacokinetic data ofWYC02 andWYC0209 needs
to be compared in future studies to determine the differ-
ences in the chemical effects of these 2 compounds in vitro
and in vivo.
Discussion
Many chemotherapeutic agents kill cancers by inter-
fering with DNA metabolism and lethally damaging
the DNA. ATM and ATR are defined as the key check-
point sensors in the DDR. Before the recent discovery of
ATR inhibitors (10–14), ATM and Chk1/2 inhibitors
were proven to efficiently enhance the sensitivity of
cancers to IR therapy or chemical agents (8). Because
the effects of flavonoids on ATR signaling have not yet
been investigated, we consider the findings of our study
to be novel. The synthetic derivative of WYC02,
WYC0209, was found to have similar, yet more potent,
inhibitory effects on ATR signaling that further validate
our findings.
Lowdoses ofWYCs significantly slowed cancer growth
and caused S-phase delay and inhibition of DNA synthe-
sis (Supplementary Fig. S5); these events are similar to
previously reported ATR defects (32). WYCs treatment
exhibited selective inhibition of ATR signaling, which we
determined experimentally by different types of DNA-
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damage inducers. We clearly indicated that KU55933
specifically inhibits the ATM-mediated phosphorylation
of Chk2 andWYCs specifically inhibit the ATR-mediated
phosphorylation of Chk1 (Figs. 2A and 3A). Because the
ATM activation that normally follows replication fork
stalling or UV-induced irradiation damage depends on
ATRkinase activity (33), theWYCs-mediated reduction in
ATM activation upon HU, but not H2O2, treatment
might result from ATR kinase dysfunction (Figs. 2A
and 3A). This specificity was also supported by our
observation that the WYC-mediated inhibition of DNA
damage-induced Chk1 phosphorylation was dependent
on ATR but not on ATM and DNA-PKcs (Fig. 3B and
Supplementary Fig. S3). Furthermore, radial changes in
chromosome structure are characteristics of cells
derived from Fanconi anemia patients but not from
patients with Ataxia telangiectasia (AT) or AT-like dis-
ease (34, 35); therefore, the WYC02-mediated inhibition
of ATR-dependent FANCD2 activation links this effect
to radial changes in chromosome structure from FA
patients (Fig. 1B).
UV-induced Chk1 phosphorylation can be restored
by overexpression of claspin and ATR but not TopBP1
or ATRIP (Fig. 3C). These data suggest that WYC02
might block the function of ATR kinase itself or the
ATR–claspin–Chk1 interactions that then affect Chk1
activation. However, we could not exclude the possi-
bility that WYCs target other mediators involved in
ATR kinase activation. For example, FANCM has been
shown to be necessary for both ATR activation and
FANCD2 monoubiquitination (36). It remains unclear
as to whether WYCs actually inhibit the ATR kinase
enzyme activity or just abort the process of activation,
and further investigations are required to clarify the
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precise mechanism(s) of action byWYCs. We screened a
human kinome set for WYC02 involving 58 diverse in
vitro kinase assays (Kinome Diversity Screen; MDS
Pharma Services) and found that only PLK1 and SGK2
kinases were moderately inhibited by a high dose of
WYC02 (Supplementary Fig. S6); therefore, it is clear
that WYC02 does not target any of the kinases tested in
this assay.
Our results supported 2 possible mechanisms by
which WYCs could enhance cancer cell sensitivity to
cisplatin: first, inhibition of the ATR checkpoint could
lead cells that carry erroneous DNA into the next gen-
eration; second, inhibition of the FA repair pathway
could result in elevated DNA DSB formation and error
accumulation. We showed that WYCs compromise the
cisplatin-induced checkpoint and lead to DSB accumu-
lation within mitotic cells (Fig. 4A and C), suggesting
that mitotic catastrophe might be induced in WYC-
treated cells, whose DNA replication was not completed
before entering into mitosis (37). Although ATM inhi-
bition by KU55933 treatment rapidly accumulates dam-
age in the late S and G2-phase cells rather than in the M-
phase cells (38), and induces cell death via apoptosis
(39), WYC02 treatment mainly causes cells to undergo
necrosis-like death rather than apoptosis in our system
(Supplementary Fig. S7). These results indicate that the
inhibition of ATM or ATR differentially cause accumu-
lation of DNA lesions in cells undergoing diverse fates
via different death pathways.
Previousdata suggest thatATRandATMplaydifferent
roles inpreventingDSB formation throughHRR (40).ATR
and its targets, such as Chk1, FANCD2, and WRN, are
required to repair cells damaged during the S-phase via
HRR (26, 29, 40, 41). We found that low doses of WYCs
almost completely inhibited the HRR-mediated repair of
chromosomal breaks, even in cells that possessed ATM
function (Fig. 4B). Although ATM-deficient cells did not
show reduced frequency of HRR to repair introduced
DSBs (42), ATM-dependent FANCD2 Ser222 phosphory-
lation is required for the intra-S checkpoint, whereas the
ATR-dependent FANCD2 Lys561 monoubiquitination is
necessary for HRR (41). In the specific case of recovering
from a stalled replication fork, we propose that ATM and
ATR collaborate to induce checkpoint activation and
recruit repair proteins for the initial step of HRR, whereas
ATR signaling perhaps plays an indispensable role in the
entire HRR process.
Our data revealed that WYCs could not only modify
cancer cell responses to cisplatin but also to other
therapeutic agents that induce Chk1 phosphorylation
(Figs. 3A, 5A, and Supplementary Fig. S2), suggesting
that WYCs may potentially function as cancer cell
sensitizers for chemotherapeutic agents that activate
the ATR checkpoint. Inhibition of DNA damage check-
points and repair factors, such as ATM and BRCA1, are
associated with promoting carcinogenesis as a conse-
quence of genomic instability (43). However, there is
no known cancer associated with ATR gene alterations.
Specific ATR inhibition by expression of kinase-inac-
tive ATR specifically in the skin prevents UV-induced
skin carcinogenesis (44), suggesting that ATR inhibi-
tion has chemopreventive effects on nontransformed
cells. Conversely, ATR has been proposed to play a
critical role in directing cell death by senescence in
unperturbed cells, where ATR is activated by over-
expression of the oncoprotein Mos or the ATR activator
TopBP1, respectively (45, 46). One plausible explana-
tion proposed by Kawasumi and colleagues is that
chemoprevention by ATR inhibition only works on
precancerous cells in which oncogenes are not yet
activated (44). In DNA-perturbed cells, the difference
in the lesions induced by various DNA-damaging
agents could also explain the different consequences
of ATR/Chk1 inhibition, such as whether this inhibi-
tion promotes or suppresses apoptosis (47). However,
while ATR activation clearly protects cells from death
via suppression of apoptosis when DNA damage is
caused by oncogene-induced replication stress or DNA
cross-linking, limited ATR activity selectively kills
these cells (48–50), probably mediated by an ATM-
dependent mitotic catastrophe (51). Taken together,
the genetic and pharmacologic evidence suggests that
ATR inhibition potentially plays a dual role by achiev-
ing both chemoprevention and chemotherapy. Given
that the efficiency of ATR inhibition causes the oppo-
site effect of synthetic lethality or tumorigenesis on
Ras-transformed cells (52), inhibition of ATR function
for anticancer therapy should be carefully evaluated
by considering the genetic background and respon-
siveness of the tumor to this type of therapy; further-
more, the efficiency of ATR inhibition should be cau-
tiously monitored during treatment.
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